Effects of subcutaneous c1-esterase inhibitor on coagulation and fibrinolytic parameters

Replacement therapy with subcutaneous C1-esterase inhibitor (C1-INH[SC]) 60 IU/kg twice weekly is approved for routine prophylaxis to prevent hereditary angioedema (HAE) attacks. Coagulation and fibrinolytic parameters levels tend to be elevated in HAE patients. We evaluated the effects of C1-INH(SC) on these parameters.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Reshef, D. Levy, B. Zuraw, H. Longhurst, M. Cicardi, T. Craig, P. Keith, H. Feuersenger, I. Pragst, J. Chiao, S. Prusty, T. Machnig, I. Jacobs Tags: P155 Source Type: research